New combo aims to wipe out breast cancer before surgery
NCT ID NCT06967103
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the drug QL1706 to standard chemotherapy before surgery can eliminate more cancer in people with early HR+/HER2- breast cancer. About 238 participants will receive either the combination or chemo alone for 6 cycles, then have surgery. After surgery, they continue QL1706 for up to 6 months. The main goal is to see if no cancer remains in the removed tissue.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Henan cancer hospital
RECRUITINGZhengzhou, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?